Terry Fry
Concepts (466)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 42 | 2026 | 337 | 9.810 |
Why?
| | T-Lymphocytes | 60 | 2026 | 1982 | 6.420 |
Why?
| | Antigens, CD19 | 27 | 2026 | 129 | 4.590 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 16 | 2026 | 89 | 4.390 |
Why?
| | Graft vs Host Disease | 20 | 2023 | 264 | 3.430 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 13 | 2026 | 21 | 3.300 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2025 | 293 | 3.160 |
Why?
| | CD8-Positive T-Lymphocytes | 19 | 2025 | 917 | 2.900 |
Why?
| | Hematopoietic Stem Cell Transplantation | 26 | 2023 | 675 | 2.830 |
Why?
| | Receptors, Antigen, T-Cell | 18 | 2023 | 668 | 2.770 |
Why?
| | Immunotherapy | 16 | 2024 | 653 | 2.540 |
Why?
| | Interleukin-7 | 23 | 2012 | 65 | 2.320 |
Why?
| | Dendritic Cells | 12 | 2026 | 499 | 2.320 |
Why?
| | CD4-Positive T-Lymphocytes | 12 | 2026 | 1129 | 1.870 |
Why?
| | Cancer Vaccines | 9 | 2018 | 160 | 1.840 |
Why?
| | Hematologic Neoplasms | 8 | 2023 | 161 | 1.680 |
Why?
| | Leukemia, Myeloid, Acute | 6 | 2025 | 682 | 1.660 |
Why?
| | Lymphoma, B-Cell | 8 | 2025 | 132 | 1.590 |
Why?
| | Bone Marrow Transplantation | 9 | 2023 | 294 | 1.220 |
Why?
| | Lymphocyte Transfusion | 4 | 2017 | 20 | 1.190 |
Why?
| | Adoptive Transfer | 10 | 2019 | 198 | 1.120 |
Why?
| | Graft vs Leukemia Effect | 4 | 2017 | 12 | 0.960 |
Why?
| | Mice | 46 | 2026 | 18339 | 0.950 |
Why?
| | Cytokines | 12 | 2022 | 2061 | 0.910 |
Why?
| | Animals | 62 | 2026 | 38058 | 0.890 |
Why?
| | Dipeptides | 3 | 2014 | 57 | 0.880 |
Why?
| | Antigens, Neoplasm | 5 | 2019 | 271 | 0.880 |
Why?
| | H-Y Antigen | 5 | 2013 | 11 | 0.870 |
Why?
| | T-Box Domain Proteins | 1 | 2025 | 106 | 0.850 |
Why?
| | Neoplasms | 13 | 2023 | 2875 | 0.830 |
Why?
| | Cell Line, Tumor | 16 | 2025 | 3540 | 0.810 |
Why?
| | Graft vs Tumor Effect | 3 | 2021 | 8 | 0.790 |
Why?
| | Humans | 115 | 2026 | 144759 | 0.720 |
Why?
| | Tumor Escape | 3 | 2021 | 49 | 0.700 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 10 | 0.700 |
Why?
| | Cell Adhesion Molecules | 1 | 2022 | 178 | 0.680 |
Why?
| | Immune System | 5 | 2010 | 179 | 0.670 |
Why?
| | Receptors, Cytokine | 2 | 2024 | 36 | 0.670 |
Why?
| | Perforin | 1 | 2020 | 21 | 0.660 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2018 | 41 | 0.660 |
Why?
| | Leukemia | 5 | 2025 | 245 | 0.650 |
Why?
| | Thymus Gland | 6 | 2004 | 311 | 0.650 |
Why?
| | Retinal Neoplasms | 1 | 2020 | 37 | 0.640 |
Why?
| | Retinoblastoma | 1 | 2020 | 42 | 0.640 |
Why?
| | WT1 Proteins | 2 | 2018 | 12 | 0.640 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2025 | 928 | 0.620 |
Why?
| | Recurrence | 13 | 2025 | 1135 | 0.600 |
Why?
| | Myelodysplastic Syndromes | 5 | 2023 | 147 | 0.600 |
Why?
| | Lymphoma | 2 | 2019 | 232 | 0.600 |
Why?
| | T-Lymphocyte Subsets | 6 | 2023 | 415 | 0.600 |
Why?
| | Transplantation, Homologous | 9 | 2018 | 415 | 0.600 |
Why?
| | Adjuvants, Immunologic | 4 | 2014 | 245 | 0.590 |
Why?
| | Erythropoietin | 1 | 2020 | 100 | 0.580 |
Why?
| | Allergy and Immunology | 1 | 2019 | 42 | 0.580 |
Why?
| | Neoplasms, Experimental | 2 | 2019 | 173 | 0.580 |
Why?
| | Mice, Inbred C57BL | 17 | 2021 | 5992 | 0.520 |
Why?
| | Genetic Engineering | 2 | 2019 | 93 | 0.500 |
Why?
| | Child | 36 | 2026 | 22633 | 0.500 |
Why?
| | Boron Compounds | 2 | 2014 | 29 | 0.500 |
Why?
| | Calcitonin | 1 | 2016 | 27 | 0.500 |
Why?
| | Hematopoietic Stem Cells | 4 | 2016 | 420 | 0.490 |
Why?
| | Immunologic Memory | 8 | 2025 | 366 | 0.490 |
Why?
| | Cell Lineage | 2 | 2016 | 376 | 0.480 |
Why?
| | Disease Models, Animal | 8 | 2026 | 4557 | 0.470 |
Why?
| | Cell Plasticity | 1 | 2016 | 37 | 0.470 |
Why?
| | Lymphocyte Activation | 11 | 2021 | 1126 | 0.470 |
Why?
| | Leukapheresis | 2 | 2017 | 27 | 0.460 |
Why?
| | Antigens, CD | 2 | 2017 | 555 | 0.450 |
Why?
| | Mice, Knockout | 8 | 2026 | 3121 | 0.450 |
Why?
| | Donor Selection | 1 | 2015 | 79 | 0.440 |
Why?
| | Apoptosis | 8 | 2019 | 2430 | 0.430 |
Why?
| | STAT1 Transcription Factor | 1 | 2014 | 68 | 0.420 |
Why?
| | Homeostasis | 6 | 2006 | 640 | 0.420 |
Why?
| | Photopheresis | 2 | 2011 | 9 | 0.420 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2014 | 46 | 0.410 |
Why?
| | Rhabdomyosarcoma | 2 | 2014 | 64 | 0.400 |
Why?
| | Signal Transduction | 8 | 2025 | 5226 | 0.400 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 233 | 0.400 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2024 | 881 | 0.390 |
Why?
| | Recombinant Fusion Proteins | 4 | 2017 | 675 | 0.390 |
Why?
| | Vaccination | 2 | 2012 | 1423 | 0.390 |
Why?
| | Boronic Acids | 1 | 2013 | 37 | 0.380 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2012 | 15 | 0.380 |
Why?
| | Lymphocyte Depletion | 8 | 2014 | 132 | 0.380 |
Why?
| | Female | 52 | 2026 | 78271 | 0.380 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 207 | 0.370 |
Why?
| | Young Adult | 20 | 2026 | 14105 | 0.370 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 442 | 0.360 |
Why?
| | Adult | 33 | 2026 | 40449 | 0.360 |
Why?
| | Flow Cytometry | 6 | 2020 | 1173 | 0.360 |
Why?
| | Siblings | 4 | 2014 | 195 | 0.360 |
Why?
| | Adolescent | 26 | 2026 | 22428 | 0.350 |
Why?
| | Antigens, CD34 | 2 | 2011 | 88 | 0.350 |
Why?
| | Mice, Inbred C3H | 4 | 2014 | 251 | 0.350 |
Why?
| | Neurotoxicity Syndromes | 2 | 2024 | 38 | 0.340 |
Why?
| | Living Donors | 3 | 2014 | 280 | 0.340 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 29 | 0.340 |
Why?
| | Protein Domains | 2 | 2025 | 313 | 0.330 |
Why?
| | Neoplasm, Residual | 3 | 2020 | 139 | 0.330 |
Why?
| | Antigen Presentation | 2 | 2009 | 205 | 0.330 |
Why?
| | Neoplasm Metastasis | 3 | 2016 | 688 | 0.320 |
Why?
| | Male | 43 | 2026 | 72315 | 0.320 |
Why?
| | Receptors, Interleukin-7 | 5 | 2011 | 28 | 0.310 |
Why?
| | Transplantation Conditioning | 4 | 2018 | 186 | 0.300 |
Why?
| | Lymphocyte Count | 4 | 2017 | 164 | 0.300 |
Why?
| | Child, Preschool | 17 | 2026 | 11787 | 0.300 |
Why?
| | Gene Expression | 5 | 2020 | 1490 | 0.300 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2009 | 255 | 0.290 |
Why?
| | Interleukin-10 | 1 | 2011 | 309 | 0.290 |
Why?
| | Receptors, Interferon | 1 | 2009 | 60 | 0.290 |
Why?
| | Sarcoma, Ewing | 2 | 2012 | 102 | 0.280 |
Why?
| | Models, Immunological | 4 | 2020 | 100 | 0.280 |
Why?
| | Mice, Transgenic | 8 | 2026 | 2182 | 0.270 |
Why?
| | Monocytes | 1 | 2011 | 538 | 0.270 |
Why?
| | Remission Induction | 4 | 2017 | 307 | 0.270 |
Why?
| | Social Adjustment | 1 | 2008 | 64 | 0.270 |
Why?
| | Clinical Trials as Topic | 4 | 2019 | 1053 | 0.260 |
Why?
| | Mutation | 2 | 2015 | 4089 | 0.260 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 467 | 0.260 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 257 | 0.260 |
Why?
| | Carcinoma | 1 | 2009 | 228 | 0.250 |
Why?
| | Receptors, Antigen | 2 | 2017 | 14 | 0.250 |
Why?
| | Gene Rearrangement | 2 | 2024 | 155 | 0.240 |
Why?
| | Allografts | 3 | 2018 | 150 | 0.240 |
Why?
| | Treatment Outcome | 14 | 2026 | 11679 | 0.240 |
Why?
| | Lymphopoiesis | 2 | 2006 | 27 | 0.240 |
Why?
| | Chemokine CCL3 | 1 | 2026 | 26 | 0.240 |
Why?
| | Neuroblastoma | 2 | 2021 | 174 | 0.230 |
Why?
| | Interferon-gamma | 1 | 2009 | 784 | 0.230 |
Why?
| | Prognosis | 7 | 2020 | 4282 | 0.220 |
Why?
| | Macrophages | 2 | 2026 | 1511 | 0.220 |
Why?
| | Unsupervised Machine Learning | 1 | 2025 | 22 | 0.220 |
Why?
| | Immunocompromised Host | 2 | 2010 | 201 | 0.220 |
Why?
| | Stem Cell Transplantation | 1 | 2006 | 191 | 0.220 |
Why?
| | Philadelphia Chromosome | 1 | 2024 | 18 | 0.220 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2025 | 45 | 0.220 |
Why?
| | Unrelated Donors | 3 | 2023 | 38 | 0.220 |
Why?
| | Disease Progression | 5 | 2021 | 2847 | 0.220 |
Why?
| | Tissue Donors | 4 | 2018 | 424 | 0.210 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 1137 | 0.210 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2025 | 223 | 0.210 |
Why?
| | Transplantation, Autologous | 5 | 2018 | 290 | 0.210 |
Why?
| | HIV Infections | 5 | 2008 | 3154 | 0.210 |
Why?
| | Berylliosis | 1 | 2026 | 202 | 0.200 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2024 | 70 | 0.200 |
Why?
| | Lentivirus | 3 | 2019 | 60 | 0.200 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2017 | 389 | 0.200 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 2 | 2014 | 35 | 0.200 |
Why?
| | Combined Modality Therapy | 4 | 2021 | 1266 | 0.190 |
Why?
| | Interleukin-15 | 4 | 2014 | 97 | 0.190 |
Why?
| | Regeneration | 2 | 2004 | 197 | 0.190 |
Why?
| | Protein Binding | 3 | 2025 | 2273 | 0.190 |
Why?
| | fms-Like Tyrosine Kinase 3 | 1 | 2023 | 49 | 0.190 |
Why?
| | Genetic Vectors | 3 | 2019 | 337 | 0.180 |
Why?
| | Mice, SCID | 4 | 2019 | 369 | 0.180 |
Why?
| | Burkitt Lymphoma | 1 | 2022 | 62 | 0.180 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 199 | 0.180 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2002 | 92 | 0.180 |
Why?
| | Gangliosides | 1 | 2021 | 23 | 0.170 |
Why?
| | Microglia | 1 | 2024 | 268 | 0.170 |
Why?
| | Lymphopenia | 4 | 2011 | 65 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2023 | 205 | 0.170 |
Why?
| | Coculture Techniques | 2 | 2012 | 246 | 0.170 |
Why?
| | Bone Marrow | 3 | 2020 | 304 | 0.170 |
Why?
| | Capillary Leak Syndrome | 1 | 2020 | 12 | 0.170 |
Why?
| | Exotoxins | 1 | 2020 | 16 | 0.160 |
Why?
| | Macrophage Activation Syndrome | 1 | 2020 | 22 | 0.160 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2021 | 72 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 780 | 0.160 |
Why?
| | Recovery of Function | 1 | 2005 | 707 | 0.160 |
Why?
| | Immunotoxins | 1 | 2020 | 55 | 0.160 |
Why?
| | Anxiety | 1 | 2008 | 1109 | 0.160 |
Why?
| | Cyclophosphamide | 4 | 2023 | 266 | 0.160 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 12 | 0.160 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 610 | 0.160 |
Why?
| | Bacterial Toxins | 1 | 2020 | 109 | 0.160 |
Why?
| | B-Lymphocytes | 4 | 2018 | 876 | 0.150 |
Why?
| | Immunodominant Epitopes | 2 | 2012 | 27 | 0.150 |
Why?
| | Clinical Studies as Topic | 1 | 2019 | 12 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2019 | 13 | 0.150 |
Why?
| | Cell Proliferation | 6 | 2024 | 2496 | 0.150 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2021 | 141 | 0.150 |
Why?
| | Pediatrics | 1 | 2008 | 1114 | 0.150 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 17 | 0.150 |
Why?
| | Epitopes | 2 | 2018 | 485 | 0.150 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1047 | 0.140 |
Why?
| | Cell Membrane | 2 | 2020 | 706 | 0.140 |
Why?
| | Immunomodulation | 1 | 2019 | 101 | 0.140 |
Why?
| | History, 21st Century | 1 | 2019 | 219 | 0.140 |
Why?
| | Immunologic Factors | 1 | 2020 | 255 | 0.140 |
Why?
| | Multiple Myeloma | 1 | 2021 | 291 | 0.140 |
Why?
| | Cryopreservation | 1 | 2019 | 110 | 0.140 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2018 | 80 | 0.140 |
Why?
| | History, 20th Century | 1 | 2019 | 325 | 0.140 |
Why?
| | Autoantigens | 2 | 2019 | 429 | 0.140 |
Why?
| | Membrane Proteins | 1 | 2004 | 1166 | 0.130 |
Why?
| | Graft Survival | 3 | 2011 | 526 | 0.130 |
Why?
| | Cell Division | 3 | 2012 | 766 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2012 | 1953 | 0.130 |
Why?
| | Secondary Prevention | 1 | 2019 | 254 | 0.130 |
Why?
| | Follow-Up Studies | 5 | 2021 | 5408 | 0.130 |
Why?
| | Down Syndrome | 1 | 2024 | 534 | 0.130 |
Why?
| | Fas Ligand Protein | 2 | 2019 | 60 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2020 | 509 | 0.130 |
Why?
| | Salvage Therapy | 2 | 2023 | 162 | 0.130 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 732 | 0.130 |
Why?
| | Chromatin | 2 | 2023 | 561 | 0.130 |
Why?
| | Immunophenotyping | 2 | 2020 | 322 | 0.130 |
Why?
| | Cell Engineering | 1 | 2017 | 14 | 0.130 |
Why?
| | Spine | 1 | 2018 | 182 | 0.120 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 375 | 0.120 |
Why?
| | Lymph Nodes | 3 | 2013 | 502 | 0.120 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 206 | 0.120 |
Why?
| | Stem Cell Research | 1 | 2016 | 1 | 0.120 |
Why?
| | CD4 Lymphocyte Count | 4 | 2008 | 277 | 0.120 |
Why?
| | Receptors, Calcium-Sensing | 1 | 2015 | 6 | 0.120 |
Why?
| | Stem Cell Niche | 1 | 2016 | 58 | 0.120 |
Why?
| | Clone Cells | 1 | 2016 | 266 | 0.120 |
Why?
| | Retrospective Studies | 9 | 2023 | 17066 | 0.120 |
Why?
| | PAX5 Transcription Factor | 1 | 2015 | 14 | 0.120 |
Why?
| | Infant | 8 | 2018 | 10034 | 0.120 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 2194 | 0.110 |
Why?
| | Janus Kinases | 1 | 2015 | 20 | 0.110 |
Why?
| | STAT Transcription Factors | 1 | 2015 | 24 | 0.110 |
Why?
| | Transcription Factors | 1 | 2023 | 1741 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 230 | 0.110 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 192 | 0.110 |
Why?
| | Gene Editing | 1 | 2016 | 93 | 0.110 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2015 | 23 | 0.110 |
Why?
| | Myeloid Cells | 1 | 2016 | 148 | 0.110 |
Why?
| | Cell Line | 2 | 2017 | 2882 | 0.110 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 377 | 0.110 |
Why?
| | 4-1BB Ligand | 1 | 2014 | 7 | 0.110 |
Why?
| | Prospective Studies | 5 | 2023 | 7990 | 0.110 |
Why?
| | Aging | 3 | 2002 | 1966 | 0.110 |
Why?
| | Calgranulin B | 1 | 2014 | 10 | 0.110 |
Why?
| | Growth | 1 | 1994 | 49 | 0.110 |
Why?
| | Calgranulin A | 1 | 2014 | 11 | 0.110 |
Why?
| | Virus Replication | 1 | 2017 | 529 | 0.110 |
Why?
| | Mice, 129 Strain | 1 | 2014 | 86 | 0.110 |
Why?
| | Models, Biological | 3 | 2009 | 1821 | 0.100 |
Why?
| | Survival Analysis | 2 | 2017 | 1382 | 0.100 |
Why?
| | Growth Disorders | 1 | 1994 | 86 | 0.100 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2014 | 70 | 0.100 |
Why?
| | Attitude to Health | 2 | 2008 | 436 | 0.100 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1253 | 0.100 |
Why?
| | Genome | 1 | 2016 | 306 | 0.100 |
Why?
| | Phenotype | 4 | 2019 | 3162 | 0.100 |
Why?
| | Erythrocytes | 1 | 2020 | 757 | 0.100 |
Why?
| | Recombinant Proteins | 6 | 2011 | 1370 | 0.100 |
Why?
| | Body Height | 1 | 1994 | 202 | 0.100 |
Why?
| | Transduction, Genetic | 3 | 2019 | 133 | 0.100 |
Why?
| | fas Receptor | 2 | 2019 | 92 | 0.100 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2014 | 124 | 0.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2014 | 177 | 0.100 |
Why?
| | Alternative Splicing | 1 | 2015 | 247 | 0.100 |
Why?
| | Incidence | 2 | 2018 | 2879 | 0.100 |
Why?
| | Animals, Congenic | 1 | 2012 | 9 | 0.100 |
Why?
| | Radiation Chimera | 1 | 2012 | 27 | 0.100 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2012 | 58 | 0.100 |
Why?
| | Proteins | 1 | 2019 | 1021 | 0.100 |
Why?
| | CD3 Complex | 3 | 2017 | 111 | 0.090 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 54 | 0.090 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2012 | 47 | 0.090 |
Why?
| | Treatment Failure | 2 | 2014 | 365 | 0.090 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2012 | 68 | 0.090 |
Why?
| | Tumor Burden | 1 | 2013 | 319 | 0.090 |
Why?
| | Chemokines | 1 | 2013 | 218 | 0.090 |
Why?
| | Antigen-Presenting Cells | 2 | 2010 | 160 | 0.090 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 346 | 0.090 |
Why?
| | Body Weight | 2 | 2002 | 976 | 0.090 |
Why?
| | Blood Component Removal | 1 | 2011 | 28 | 0.090 |
Why?
| | CD28 Antigens | 2 | 2025 | 58 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2015 | 780 | 0.090 |
Why?
| | CD4-CD8 Ratio | 2 | 2019 | 23 | 0.090 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 684 | 0.090 |
Why?
| | Methoxsalen | 1 | 2011 | 4 | 0.080 |
Why?
| | Adenovirus Infections, Human | 1 | 2010 | 15 | 0.080 |
Why?
| | Spleen | 2 | 2011 | 508 | 0.080 |
Why?
| | Brain Neoplasms | 2 | 2011 | 1318 | 0.080 |
Why?
| | Cytosine | 1 | 2010 | 51 | 0.080 |
Why?
| | Blood | 1 | 2011 | 109 | 0.080 |
Why?
| | Alleles | 1 | 2013 | 879 | 0.080 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2002 | 278 | 0.080 |
Why?
| | Organophosphonates | 1 | 2010 | 97 | 0.080 |
Why?
| | Hematopoiesis | 3 | 2016 | 194 | 0.080 |
Why?
| | Antiviral Agents | 2 | 2018 | 767 | 0.080 |
Why?
| | Transplantation Immunology | 1 | 2009 | 29 | 0.080 |
Why?
| | Ophthalmoplegia | 1 | 1989 | 13 | 0.080 |
Why?
| | Acute Disease | 3 | 2023 | 1030 | 0.080 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 1989 | 29 | 0.070 |
Why?
| | Laryngeal Neoplasms | 1 | 1989 | 35 | 0.070 |
Why?
| | Intestinal Neoplasms | 1 | 2009 | 30 | 0.070 |
Why?
| | Sarcoma | 1 | 2011 | 205 | 0.070 |
Why?
| | Hematopoietic System | 1 | 2008 | 7 | 0.070 |
Why?
| | Virus Diseases | 1 | 2011 | 216 | 0.070 |
Why?
| | Interleukin-12 | 1 | 2009 | 117 | 0.070 |
Why?
| | Sibling Relations | 1 | 2008 | 10 | 0.070 |
Why?
| | Substrate Specificity | 1 | 2009 | 388 | 0.070 |
Why?
| | Cell Differentiation | 4 | 2023 | 2050 | 0.070 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2008 | 52 | 0.070 |
Why?
| | Ultraviolet Rays | 1 | 2011 | 388 | 0.070 |
Why?
| | Lymphocyte Subsets | 2 | 2014 | 83 | 0.070 |
Why?
| | Psychology | 1 | 2008 | 88 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2014 | 847 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2014 | 4154 | 0.060 |
Why?
| | Tumor Cells, Cultured | 1 | 2009 | 919 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 863 | 0.060 |
Why?
| | Middle Aged | 9 | 2025 | 35875 | 0.060 |
Why?
| | Biomarkers | 2 | 2016 | 4271 | 0.060 |
Why?
| | Macaca fascicularis | 2 | 2007 | 71 | 0.060 |
Why?
| | Immune Tolerance | 2 | 2010 | 379 | 0.060 |
Why?
| | Chemokine CCL4 | 1 | 2026 | 31 | 0.060 |
Why?
| | Aged | 7 | 2025 | 25913 | 0.060 |
Why?
| | Ki-67 Antigen | 2 | 2004 | 117 | 0.060 |
Why?
| | Brain | 1 | 2018 | 2933 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 240 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2022 | 1054 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2004 | 25 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1989 | 641 | 0.050 |
Why?
| | Hemostasis | 1 | 2004 | 102 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 205 | 0.050 |
Why?
| | United States | 4 | 2018 | 15966 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2024 | 266 | 0.050 |
Why?
| | Obesity | 2 | 2022 | 3077 | 0.050 |
Why?
| | CD47 Antigen | 1 | 2023 | 42 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2006 | 463 | 0.040 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2002 | 16 | 0.040 |
Why?
| | Histocompatibility Testing | 2 | 2014 | 121 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 341 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2022 | 183 | 0.040 |
Why?
| | Cohort Studies | 3 | 2014 | 5960 | 0.040 |
Why?
| | United Kingdom | 2 | 2009 | 338 | 0.040 |
Why?
| | Thymectomy | 1 | 2001 | 15 | 0.040 |
Why?
| | Body Mass Index | 1 | 2009 | 2438 | 0.040 |
Why?
| | Pyrimidines | 1 | 2024 | 532 | 0.040 |
Why?
| | HIV Protease Inhibitors | 1 | 2001 | 69 | 0.040 |
Why?
| | Pyrazoles | 1 | 2024 | 509 | 0.040 |
Why?
| | Ritonavir | 1 | 2001 | 75 | 0.040 |
Why?
| | Skin Transplantation | 1 | 2001 | 85 | 0.040 |
Why?
| | Cell Survival | 2 | 2019 | 1098 | 0.040 |
Why?
| | NF-kappa B | 1 | 2024 | 661 | 0.040 |
Why?
| | Peptides | 1 | 2026 | 995 | 0.040 |
Why?
| | Lymphocytes | 1 | 2002 | 382 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 307 | 0.040 |
Why?
| | Subcutaneous Emphysema | 1 | 1999 | 1 | 0.040 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2019 | 9 | 0.040 |
Why?
| | Mice, Nude | 1 | 2001 | 682 | 0.040 |
Why?
| | Vulva | 1 | 1999 | 23 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 623 | 0.040 |
Why?
| | Single-Chain Antibodies | 1 | 2019 | 15 | 0.040 |
Why?
| | Up-Regulation | 3 | 2008 | 851 | 0.040 |
Why?
| | K562 Cells | 1 | 2019 | 93 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2011 | 2919 | 0.040 |
Why?
| | Immunization | 1 | 2001 | 374 | 0.040 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 1999 | 21 | 0.040 |
Why?
| | Age Factors | 3 | 2011 | 3333 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 267 | 0.040 |
Why?
| | Transgenes | 1 | 2019 | 189 | 0.040 |
Why?
| | Mental Status and Dementia Tests | 1 | 2018 | 26 | 0.040 |
Why?
| | Hallucinations | 1 | 2018 | 31 | 0.040 |
Why?
| | Confusion | 1 | 2018 | 30 | 0.040 |
Why?
| | Cancer Care Facilities | 1 | 2018 | 48 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 175 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 140 | 0.030 |
Why?
| | Steroids | 1 | 2018 | 160 | 0.030 |
Why?
| | Risk Factors | 4 | 2018 | 10779 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 323 | 0.030 |
Why?
| | Gene Order | 1 | 2017 | 27 | 0.030 |
Why?
| | Graft Rejection | 1 | 2001 | 540 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 197 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 432 | 0.030 |
Why?
| | Advisory Committees | 1 | 2018 | 228 | 0.030 |
Why?
| | Transfection | 1 | 2019 | 940 | 0.030 |
Why?
| | Weight Loss | 1 | 2002 | 836 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 744 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 769 | 0.030 |
Why?
| | Cell Cycle | 1 | 2019 | 596 | 0.030 |
Why?
| | Research Subjects | 1 | 2016 | 41 | 0.030 |
Why?
| | Protein Engineering | 1 | 2017 | 122 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2016 | 41 | 0.030 |
Why?
| | Time Factors | 4 | 2008 | 7173 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2017 | 455 | 0.030 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2015 | 26 | 0.030 |
Why?
| | Medical Oncology | 1 | 2018 | 332 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2017 | 313 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 400 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 6048 | 0.030 |
Why?
| | Anti-HIV Agents | 1 | 2002 | 888 | 0.030 |
Why?
| | Transplantation Chimera | 1 | 2014 | 56 | 0.030 |
Why?
| | Chimera | 1 | 2014 | 61 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2018 | 6429 | 0.030 |
Why?
| | Exons | 1 | 2015 | 358 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3409 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 887 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 437 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 251 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2001 | 2947 | 0.020 |
Why?
| | Reference Values | 1 | 1994 | 797 | 0.020 |
Why?
| | Lung | 1 | 2026 | 4109 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 1045 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 824 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2016 | 412 | 0.020 |
Why?
| | Vidarabine | 1 | 2012 | 32 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 97 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2014 | 259 | 0.020 |
Why?
| | Etoposide | 1 | 2012 | 166 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 462 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 847 | 0.020 |
Why?
| | Vincristine | 1 | 2012 | 140 | 0.020 |
Why?
| | Prednisone | 1 | 2012 | 221 | 0.020 |
Why?
| | Rituximab | 1 | 2012 | 209 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 1095 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 45 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 397 | 0.020 |
Why?
| | Bone Neoplasms | 1 | 2012 | 253 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 2009 | 45 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 710 | 0.020 |
Why?
| | Bacteremia | 1 | 2011 | 221 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1496 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 965 | 0.020 |
Why?
| | Risk | 1 | 2011 | 911 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2008 | 72 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 1989 | 333 | 0.020 |
Why?
| | Leukocytes | 1 | 2010 | 295 | 0.020 |
Why?
| | Cell Separation | 1 | 2008 | 307 | 0.020 |
Why?
| | HLA Antigens | 1 | 2008 | 225 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2832 | 0.020 |
Why?
| | HIV | 1 | 2008 | 250 | 0.020 |
Why?
| | Cell Polarity | 1 | 2007 | 137 | 0.010 |
Why?
| | Mass Screening | 1 | 1994 | 1347 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3863 | 0.010 |
Why?
| | Body Composition | 1 | 2009 | 706 | 0.010 |
Why?
| | Forkhead Transcription Factors | 1 | 2006 | 202 | 0.010 |
Why?
| | Catheter Ablation | 1 | 2009 | 353 | 0.010 |
Why?
| | Adiposity | 1 | 2009 | 543 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 320 | 0.010 |
Why?
| | Interleukins | 1 | 2006 | 248 | 0.010 |
Why?
| | Annexin A5 | 1 | 2004 | 21 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 1999 | 2730 | 0.010 |
Why?
| | Coloring Agents | 1 | 2004 | 93 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 124 | 0.010 |
Why?
| | Macaca mulatta | 1 | 2004 | 191 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 846 | 0.010 |
Why?
| | Tissue Distribution | 1 | 2004 | 327 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1985 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2008 | 2115 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2009 | 846 | 0.010 |
Why?
| | bcl-2-Associated X Protein | 1 | 2002 | 54 | 0.010 |
Why?
| | Models, Genetic | 1 | 2004 | 536 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2001 | 17 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 679 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 331 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2001 | 88 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1627 | 0.010 |
Why?
| | Colon | 1 | 2002 | 304 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1217 | 0.010 |
Why?
| | Pubic Bone | 1 | 1999 | 6 | 0.010 |
Why?
| | Genotype | 1 | 2004 | 1833 | 0.010 |
Why?
| | Hyperbaric Oxygenation | 1 | 1999 | 39 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 3671 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 1999 | 44 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 2168 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1519 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 5868 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1887 | 0.010 |
Why?
|
|
Fry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|